Apixaban

Apixaban 구조식 이미지
카스 번호:
503612-47-3
상품명:
Apixaban
동의어(영문):
1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;CS-343;pixaban;BMS562247;1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide;1H-Pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-;xaban;Apixaba;Apxaban;Apixaban
CBNumber:
CB51508586
분자식:
C25H25N5O4
포뮬러 무게:
459.5
MOL 파일:
503612-47-3.mol
MSDS 파일:
SDS

Apixaban 속성

녹는점
235-238°C
끓는 점
770.5±60.0 °C(Predicted)
밀도
1.42
저장 조건
Refrigerator
용해도
DMSO(약간 용해됨, 가열), 메탄올(약간 용해됨)
산도 계수 (pKa)
15.01±0.20(Predicted)
물리적 상태
고체
물리적 상태
단단한 모양
색상
흰색에서 황백색까지
InChIKey
QNZCBYKSOIHPEH-UHFFFAOYSA-N
SMILES
C1(=O)N(C2=CC=C(N3CCCCC3=O)C=C2)CCC2C(C(N)=O)=NN(C3=CC=C(OC)C=C3)C1=2
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
유해 물질 데이터 503612-47-3(Hazardous Substances Data)
그림문자(GHS): GHS hazard pictograms
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H361 태아 또는 생식능력에 손상을 일으킬 것으로 의심됨 생식독성 물질 구분 2 경고 P201, P202, P281, P308+P313, P405,P501
예방조치문구:
P201 사용 전 취급 설명서를 확보하시오.
P202 모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P405 밀봉하여 저장하시오.

Apixaban C화학적 특성, 용도, 생산

개요

Eliquis (apixaban), a direct inhibitor of factor Xa (FXa), was approved by the European Commission on May 18, 2011 for prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. The discovery of apixaban was the culmination of a succession of novel and innovative medicinal chemistry discoveries starting with the identification of nonpeptide leads, rational drug design using computer-aided and X-ray crystallographic information, and the building of drug-like properties through the systematic replacement of basic groups with neutral moieties. Apixaban arose from modifications to razaxaban by constraining a pyrazole amide to form a bicyclic pyrazolo-pyridinone scaffold. Optimization of the P1 group resulted in the identification of the nonbasic methoxy phenyl group, while a P4 piperidinone improved the balance of potency and pharmacokinetics with low Vdss. The synthesis of apixaban begins with the generation of a hydrazone of 4-methoxyaniline which is then used in a 3+2 cycloaddition with a dihydropiperidinone to form a bicyclic pyrazolo-pyridinone scaffold. The distal piperidinone group is installed using an Ullmann coupling reaction followed by aminolysis of an ethyl ester on the pyrazole ring to complete the synthesis of apixaban.

용도

Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.

정의

ChEBI: A pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases.

Pharmacokinetics

The maximum plasma concentration (Cmax) of apixaban occurs 3–4 h after oral administration. The absorption of apixaban appears to occur primarily in the small intestine and decreases progressively throughout the gastrointestinal tract. Compared with oral administration, the bioavailability of 2.5 mg of apixaban solution was approximately 60% and 84% lower when released in the distal small bowel and ascending colon, respectively. For oral doses up to 10 mg, the absolute bioavailability of apixaban is~50%, resulting from the incomplete absorption and first-pass metabolism in the gut and liver[1].

Clinical Use

Apixaban is an oral anticoagulant with highly selective inhibition of factor Xa. It was approved by the European Medicines Agency (EMA) for the treatment of venous thromboembolic events and first marketed in Germany under the brand name Eliquis in June 2011. Apixaban was co-developed by Bristol-Myers Squibb and Pfizer and represents the first approved drug for this indication since warfarin over 50 years ago.

부작용

Possible side effects of Apixaban are: bleeding gums, nosebleeds, heavy vaginal bleeding , red, pink, or brown urine; red or black, tarry stools; coughing or spitting up blood or a substance that looks like coffee grounds; swelling or joint pain, headache, rash, chest pain or tightness in the chest, swelling of the face or tongue, trouble breathing, wheezing. Feeling dizzy or fainting.Apixaban prevents your blood from clotting properly, so if you get a cut or injury, it may take longer than usual for the bleeding to stop. This medication may also cause you to bruise or bleed more easily.

참고 문헌

https://en.wikipedia.org/wiki/Apixaban
https://www.drugbank.ca/drugs/DB06605
[1] Wonkyung Byon. “Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review.” Clinical Pharmacokinetics 58 10 (2019): 1265–1279.

Apixaban 준비 용품 및 원자재

원자재

준비 용품


Apixaban 공급 업체

글로벌( 783)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Jinan Million Pharmaceutical Co., Ltd
+86-531-68659554 +8613031714605
info@millionpharm.com China 154 58
Jinan Jianfeng Chemical Co., Ltd
0531-88110457; +8615562555968
info@pharmachemm.com China 222 58
AFINE CHEMICALS LIMITED
0571-85134551
info@afinechem.com CHINA 15377 58
APOLLO HEALTHCARE RESOURCES
+6596580999
sales@apollo-healthcare.com.sg Singapore 400 58
Changzhou Rokechem Technology Co., Ltd.
18758118018
sales001@rokechem.com China 255 58
LEAPCHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 43348 58
ChemExpress
+86-021-58950125
info@chemexpress.com China 557 58
hebei hongtan Biotechnology Co., Ltd
+86-86-1913198-3935 +8617331935328
sales03@chemcn.cn China 951 58
Shanghai Affida new material science and technology center
+undefined15081010295
2691956269@qq.com China 359 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 5993 58

Apixaban 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved